|
Adverse Effects
Adverse effects of antineoplaston therapy have ranged from mild and short-lasting symptoms to severe neurologic toxicity necessitating discontinuation of therapy in some patients.[1]
Table 3 summarizes the adverse effects in the referenced studies.
Table 3. Adverse Effects
|
Adverse Effect
|
Reference
|
|
*The most severe adverse effects occurred in this study, which reported neurologic toxic effects such as excessive somnolence, somnolence plus confusion, and increased frequency of underlying focalmotorseizures; increased cerebral edema; and persistent confusion. In addition, the study reported myalgia, severe cutaneouserythema, pruritus, and anasarca of the extremities and face.
|
|
Anemia
|
[2,3] |
|
Blood pressure elevation |
[4,5] |
| Dizziness or vertigo |
[6,7] |
| Excess abdominal gas |
[4,8] |
|
Fever and chills |
[2,5-7,9-11]
|
| General malaise with and without anorexia |
[2,4] |
| Headaches |
[1,4,6,7] |
| Hypocalcemia and hypercalcemia |
[2,5] |
| Increased thickness of epidermis associated with skin peeling and faster-than-usual growth of nails |
[11] |
| Maculopapular or itchy skin rash |
[2,4,5,8] |
| Mild myelosuppression |
[5,8,12] |
|
Nausea and vomiting |
[1,2,5-7] |
| Neurocortical toxicity, severe |
[1]* |
| Numbness |
[2] |
| Palpitations, tachycardia, or pressure in the chest with irregular heartbeat |
[4,11,1,7]
|
| Peripheral edema, facial edema, cerebral edema |
[1,4] |
| Swelling, pain, or stiffness of small joints |
[4,8,10,11] |
References
-
Buckner JC, Malkin MG, Reed E, et al.: Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 74 (2): 137-45, 1999.
[PUBMED Abstract]
-
Burzynski SR, Lewy RI, Weaver RA, et al.: Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 4 (2): 91-101, 2003.
[PUBMED Abstract]
-
Burzynski SR, Janicki TJ, Weaver RA, et al.: Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther 5 (1): 40-7, 2006.
[PUBMED Abstract]
-
Tsuda H, Hara H, Eriguchi N, et al.: Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 42 (4): 241-9, 1995.
[PUBMED Abstract]
-
Burzynski SR, Burzynski B, Mohabbat MO: Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 12 (Suppl 1): 25-35, 1986.
[PUBMED Abstract]
-
Burzynski SR, Kubove E: Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 12 (Suppl 1): 47-55, 1986.
[PUBMED Abstract]
-
Burzynski SR, Kubove E: Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 13 (Suppl 1): 17-29, 1987.
[PUBMED Abstract]
-
Sugita Y, Tsuda H, Maruiwa H, et al.: The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Kurume Med J 42 (3): 133-40, 1995.
[PUBMED Abstract]
-
Burzynski SR, Stolzmann Z, Szopa B, et al.: Antineoplaston A in cancer therapy. (I). Physiol Chem Phys 9 (6): 485-500, 1977.
[PUBMED Abstract]
-
Burzynski SR: Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 12 (Suppl 1): 17-24, 1986.
[PUBMED Abstract]
-
Burzynski SR, Kubove E, Burzynski B: Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 13 (Suppl 1): 37-43, 1987.
[PUBMED Abstract]
-
Burzynski SR, Weaver RA, Janicki T, et al.: Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 4 (2): 168-77, 2005.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |
